Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 8/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907682 | 0.92 | AKT1 (0.43) | AKT1IKBKBCHUKROCK1NEK1 | |
| SCHEMBL14907691 | 0.86 | IKBKB (0.45) | AKT1IKBKBCHUKNEK1NUDT1 | |
| SCHEMBL14907662 | 0.85 | NUDT1 (0.44) | AKT1IKBKBCHUKROCK1NEK1 | |
| SCHEMBL14907663 | 0.84 | AKT1 (0.44) | AKT1IKBKBCHUKROCK1NEK1 | |
| SCHEMBL14907679 | 0.81 | CYP3A4 (0.44) | AKT1IKBKBCHUKROCK1NEK1 | |
| SCHEMBL14907683 | 0.80 | JAK1 (0.43) | NEK1NUDT1KLKB1 | |
| SCHEMBL14907692 | 0.78 | IKBKB (0.42) | AKT1IKBKBCHUKROCK1NEK1 | |
| SCHEMBL14907646 | 0.78 | ROCK2 (0.43) | AKT1ROCK1NUDT1PRKCICIT | |
| SCHEMBL14907654 | 0.78 | JAK2 (0.42) | NUDT1KLKB1 | |
| SCHEMBL14894355 | 0.77 | PLD2 (0.39) | IKBKBCHUKROCK1NEK1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174984-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20140296204-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-10-02 | — | — | US | disclosed |
| WO-2013062945-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296204-A1 | CHEMICAL COMPOUNDS | DNMT1, DNMT3A, DNMT3B | AKT1 887/4885IKBKB 465/4885CHUK 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.